These neurotransmitters are often impacted during perimenopause and menopause, contributing to anxiety, low mood, and irritability
Mechanisms of Action Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, stimulating pulsatile GH release and subsequent IGF-1 production, which preferentially reduces visceral adipose tissue (VAT).[1][12] It mimics endogenous GHRH, leading to lipolysis without significant effects on subcutaneous fat or glucose metabolism in target populations.[3][13] Key sub-mechanisms include: GHRH Receptor Activation : Triggers cAMP signaling to enhance GH secretion.[1][14] Physiological Feedback Regulation : Maintains axis balance, avoiding desensitization.[12][15] Pulsatile Hormone Release : Induces episodic GH patterns for sustained efficacy.[3][16] Pituitary Gene Transcription : Upregulates GH expression.[1][17] Hypothalamic-Pituitary Axis Interaction : Supports endocrine homeostasis, reducing VAT via IGF-1-mediated lipolysis.[12][18] These mechanisms highlight Tesamorelin's potential for compounding in therapies targeting visceral fat
Researchers are encouraged to consult all safety guidelines before beginning studies with this, or any other peptide
This review aims to elucidate the current and future landscape of topical exosomes and peptides as therapeutics for skin rejuvenation
doi: 10.1016/j.tim.2025.03.014 110 EngleK.KumarG
Schistosomes, Liver Flukes and Helicobacter Pylori
